Maria E. Cabanillas, MD, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.
Maria E. Cabanillas, MD, an oncologic endocrinologist, professor, and faculty director in the Department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses the treatment landscape for patients with thyroid cancers harboring a TRK fusion.
TRK fusions occur specifically in differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC), as well as poorly DTC which is classified as another type of thyroid cancer, Cabanillas says. TRK fusions have not been observed in medullary thyroid cancer, however, limiting use of larotrectinib (Vitrakvi), a TRK inhibitor, to patients with DTC and ATC who harbor the TRK fusion.
For the treatment of patients with DTC, particularly those with advanced progressive disease, the options include 2 VGEF receptor inhibitors, sorafenib (Nexavar) and lenvatinib (Lenvima), Cabanillas says. The only effective therapy in ATC, however, is for patients harboring a BRAF mutation, which is the FDA-approved combination of dabrafenib (Tafinlar) and trametinib (Mekinist). For patients with ATC who are not BRAF-mutated, there are no good therapies available at this time, according to Cabanillas.
It is important to recognize that although TRK fusions are rare in DTC and ATC, physicians should be checking for these rare fusions considering there are now selective therapies available for the population.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More